Serum Institute of India can produce 700-800 million vaccine dosages every year once things are streamlined, executive director of SII said
In its latest updates, Pune’s Serum Institute of India (SII) has disclosed that India will get 60-70 million doses of Oxford vaccine Covishield by December. However, the vaccines will come to the market in March 2021, since the time between December and March would be required for licensing, Dr Suresh Yadav, executive director of SII said at the India Vaccine Accessibility e-Summit organised by HEAL Foundation in association with ICCIDD.
SII has signed a deal with British-Swedish company AstraZeneca to manufacture COVID-19 vaccine candidate, developed by the University of Oxford. The vaccine uses a weakened version of a chimpanzee common cold virus. This encodes instructions for making proteins from the novel coronavirus to generate an immune response and prevent infection. The vaccine is likely to provide protection for about a year, AstraZeneca CEO Pascal Soriot, said earlier.
Presently, SII is at the Phase 2 and 3 of the ongoing trial of the vaccine.